BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND HOXD13, SPD, 3239, P35453, HOX4I AND Prognosis
5 results:

  • 1. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
    Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
    Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.
    Bhagat TD; Chen S; Bartenstein M; Barlowe AT; Von Ahrens D; Choudhary GS; Tivnan P; Amin E; Marcondes AM; Sanders MA; Hoogenboezem RM; Kambhampati S; Ramachandra N; Mantzaris I; Sukrithan V; Laurence R; Lopez R; Bhagat P; Giricz O; Sohal D; Wickrema A; Yeung C; Gritsman K; Aplan P; Hochedlinger K; Yu Y; Pradhan K; Zhang J; Greally JM; Mukherjee S; Pellagatti A; Boultwood J; Will B; Steidl U; Raaijmakers MHGP; Deeg HJ; Kharas MG; Verma A
    Cancer Res; 2017 Sep; 77(18):4846-4857. PubMed ID: 28684528
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
    Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
    Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.
    Rossille D; Gressier M; Damotte D; Maucort-Boulch D; Pangault C; Semana G; Le Gouill S; Haioun C; Tarte K; Lamy T; Milpied N; Fest T; ;
    Leukemia; 2014 Dec; 28(12):2367-75. PubMed ID: 24732592
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.